SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has been awarded $1,955,834 in immediately available funds from the U.S. government under HR: 3590 – Patient Protection and Affordable Care Act (the “Act”). The award comprises separate payments of approximately $245,000 for each of eight drug development programs at Ligand.
